Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)

Conditions: Kidney Transplant Rejection Interventions: Drug: Conversion to Belatacep; Drug: Standard of care treatment (SOC regimen) with Tacrolimus Sponsors: University Hospital, Rouen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials